289 related articles for article (PubMed ID: 16710033)
21. Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL).
Shanafelt T; Lanasa MC; Call TG; Beaven AW; Leis JF; LaPlant B; Bowen D; Conte M; Jelinek DF; Hanson CA; Kay NE; Zent CS
Cancer; 2013 Nov; 119(21):3788-96. PubMed ID: 23922059
[TBL] [Abstract][Full Text] [Related]
22. Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia.
Tsimberidou AM; Tam C; Abruzzo LV; O'Brien S; Wierda WG; Lerner S; Kantarjian HM; Keating MJ
Cancer; 2009 Jan; 115(2):373-80. PubMed ID: 19117034
[TBL] [Abstract][Full Text] [Related]
23. Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syndrome.
Tsimberidou AM; Wierda WG; Wen S; Plunkett W; O'Brien S; Kipps TJ; Jones JA; Badoux X; Kantarjian H; Keating MJ;
Clin Lymphoma Myeloma Leuk; 2013 Oct; 13(5):568-74. PubMed ID: 23810245
[TBL] [Abstract][Full Text] [Related]
24. Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma.
Keating GM
Drugs; 2010 Jul; 70(11):1445-76. PubMed ID: 20614951
[TBL] [Abstract][Full Text] [Related]
25. Combined fludarabine and rituximab for low grade lymphoma and chronic lymphocytic leukemia.
Savage DG; Cohen NS; Hesdorffer CS; Heitjan D; Oster MW; Garrett TJ; Bar M; del Prete S; March R; Lonberg M; Talbot S; Mears JG; Flamm M; Taub RN; Nichols G
Leuk Lymphoma; 2003 Mar; 44(3):477-81. PubMed ID: 12688318
[TBL] [Abstract][Full Text] [Related]
26. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia.
Wierda W; O'Brien S; Wen S; Faderl S; Garcia-Manero G; Thomas D; Do KA; Cortes J; Koller C; Beran M; Ferrajoli A; Giles F; Lerner S; Albitar M; Kantarjian H; Keating M
J Clin Oncol; 2005 Jun; 23(18):4070-8. PubMed ID: 15767647
[TBL] [Abstract][Full Text] [Related]
27. How we treat Richter syndrome.
Parikh SA; Kay NE; Shanafelt TD
Blood; 2014 Mar; 123(11):1647-57. PubMed ID: 24421328
[TBL] [Abstract][Full Text] [Related]
28. Long-term follow-up of advanced-stage low-grade lymphoma patients treated upfront with high-dose sequential chemotherapy and autograft.
Tarella C; Caracciolo D; Corradini P; Zallio F; Ladetto M; Cuttica A; Rossi G; Novero D; Gavarotti P; Pileri A
Leukemia; 2000 Apr; 14(4):740-7. PubMed ID: 10764164
[TBL] [Abstract][Full Text] [Related]
29. Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia.
Parikh SA; Keating MJ; O'Brien S; Wang X; Ferrajoli A; Faderl S; Burger J; Koller C; Estrov Z; Badoux X; Lerner S; Wierda WG
Blood; 2011 Aug; 118(8):2062-8. PubMed ID: 21750315
[TBL] [Abstract][Full Text] [Related]
30. Risk-adapted, treosulfan-based therapy with auto- and allo-SCT for relapsed/refractory aggressive NHL: a prospective phase-II trial.
Koenigsmann M; Casper J; Kahl C; Basara N; Sayer HG; Behre G; Theurich S; Christopeit M; Mohren M; Reichle A; Metzner B; Ganser A; Stadler M; Uharek L; Balleisen L; Hinke A; Hinke R; Niederwieser D
Bone Marrow Transplant; 2014 Mar; 49(3):410-5. PubMed ID: 24362366
[TBL] [Abstract][Full Text] [Related]
31. Rituximab reduces relapse risk after allogeneic and autologous stem cell transplantation in patients with high-risk aggressive non-Hodgkin's lymphoma.
Shimoni A; Hardan I; Avigdor A; Yeshurun M; Raanani P; Ben-Bassat I; Nagler A
Br J Haematol; 2003 Aug; 122(3):457-64. PubMed ID: 12877674
[TBL] [Abstract][Full Text] [Related]
32. Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study.
Herling CD; Coombes KR; Benner A; Bloehdorn J; Barron LL; Abrams ZB; Majewski T; Bondaruk JE; Bahlo J; Fischer K; Hallek M; Stilgenbauer S; Czerniak BA; Oakes CC; Ferrajoli A; Keating MJ; Abruzzo LV
Lancet Oncol; 2019 Nov; 20(11):1576-1586. PubMed ID: 31582354
[TBL] [Abstract][Full Text] [Related]
33. Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database.
Ban-Hoefen M; Vanderplas A; Crosby-Thompson AL; Abel GA; Czuczman MS; Gordon LI; Kaminski MS; Kelly J; Millenson M; Nademanee AP; Rodriguez MA; Zelenetz AD; Niland J; LaCasce AS; Friedberg JW
Br J Haematol; 2013 Nov; 163(4):487-95. PubMed ID: 24111533
[TBL] [Abstract][Full Text] [Related]
34. Utility of positron emission tomography-computed tomography in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy.
Mato AR; Wierda WG; Davids MS; Cheson BD; Coutre SE; Choi M; Furman RR; Heffner L; Barr PM; Eradat H; Ford SM; Zhou L; Verdugo M; Humerickhouse RA; Potluri J; Byrd JC
Haematologica; 2019 Nov; 104(11):2258-2264. PubMed ID: 30923097
[TBL] [Abstract][Full Text] [Related]
35. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.
Byrd JC; Gribben JG; Peterson BL; Grever MR; Lozanski G; Lucas DM; Lampson B; Larson RA; Caligiuri MA; Heerema NA
J Clin Oncol; 2006 Jan; 24(3):437-43. PubMed ID: 16344317
[TBL] [Abstract][Full Text] [Related]
36. Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment.
Hallek M
Am J Hematol; 2019 Nov; 94(11):1266-1287. PubMed ID: 31364186
[TBL] [Abstract][Full Text] [Related]
37. Bendamustine/mitoxantrone/rituximab: a short remission induction chemoimmunotherapy for elderly patients with relapsed or refractory chronic lymphocytic leukemia.
Weide R; Mergenthaler U; Friesenhahn V; Kleboth K; Heymanns J; Thomalla J; Köppler H
Leuk Lymphoma; 2009 Sep; 50(9):1468-74. PubMed ID: 21049589
[TBL] [Abstract][Full Text] [Related]
38. The role of rituximab in autologous and allogeneic hematopoietic stem cell transplantation for non-Hodgkin's lymphoma.
Naparstek E
Curr Hematol Malig Rep; 2006 Dec; 1(4):220-9. PubMed ID: 20425317
[TBL] [Abstract][Full Text] [Related]
39. Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results.
Khouri IF; Keating MJ; Vriesendorp HM; Reading CL; Przepiorka D; Huh YO; Andersson BS; van Besien KW; Mehra RC; Giralt SA
J Clin Oncol; 1994 Apr; 12(4):748-58. PubMed ID: 8151318
[TBL] [Abstract][Full Text] [Related]
40. Fludarabine combination therapy for the treatment of chronic lymphocytic leukemia.
Schmitt B; Wendtner CM; Bergmann M; Busch R; Franke A; Pasold R; Schlag R; Hopfinger G; Hiddemann W; Emmerich B; Hallek M
Clin Lymphoma; 2002 Jun; 3(1):26-35. PubMed ID: 12141952
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
